Author

Fumihito Hirai 1

1 Fukuoka University Chikushi Hospital

ADALIMUMAB ACHIEVES COMPLETE REMISSION AT 52 WEEKS IN JAPANESE PATIENTS WITH INTESTINAL BEHÇET'S DISEASE

Fumihito Hirai, Satoshi Tanida, Nagamu Inoue, Makoto Naganuma, Anne Camez, Bidan Huang, Vipin Arora, Morio Ozawa, Toshifumi Hibi, Roopal B Thakkar

ADDITIONAL POWER OF ELEMENTAL DIET ON MAINTENANCE BIOLOGICS THERAPY IN CROHN'S DISEASE (ADORE STUDY) - A MULTICENTER, PROSPECTIVE, COHORT STUDY

Tetsuya Ishida, Fumihito Hirai

Impact of Mirikizumab Treatment on Inflammatory Bowel Disease Questionnaire Scores in Patients with Moderate to Severely Active Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

NOVEL BIO-MARKER FOR COLORECTAL NEOPLASIA: WHITE OPAQUE SUBSTANCE WITHIN COLORECTAL NEOPLASTIC EPITHELIUM AS VISUALIZED BY MAGNIFYING ENDOSCOPY WITH NARROW-BAND IMAGING

Kentaro Imamura, Kenshi Yao, Takashi Hisabe, Takashi Nagahama, Fumihito Hirai, Masami Nambu, Akinori Iwashita

EFFICACY OF ENDOSCOPIC BALLOON DILATION FOR SMALL BOWEL STRICTURES IN PATIENTS WITH CROHN’S DISEASE: A NATIONWIDE, MULTI-CENTER, OPEN-LABEL, PROSPECTIVE COHORT STUDY

Fumihito Hirai

Safety and efficacy of endoscopic dilatation of small bowel Crohn's disease strictures by balloon-assisted enteroscopy: a pooled analysis of individual data from 219 patients

Dominik Bettenworth, Arne Bokemeyer, Lei Kou, Rocio Lopez, Brendan Halloran, Matthew Reeson, Naoki Hosomi, Masahiro Kishi, Fumihito Hirai, Naoki Ohmiya, Florian Rieder

Usefulness of ACP 353 (anti-Crohn´s disease peptide 353) as a new biomarker in the diagnosis of inflammatory bowel disease: A multicenter study

Shinichiro Yoshioka, Keiichi Mitsuyama, Fumihito Hirai, Motohiro Esaki, Toshihiro Araki, Masaru Morita, Tetsuhiro Yoshimura, Atsushi Mori, Ryosuke Yamauchi, Kotaro Kuwaki, T. Torimura

Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Ruth Belin, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

Usefulness of leucine-rich alpha-2-glycoprotein (LRG) to monitor the efficacy of adalimumab treatment in patients with ulcerative colitis (PLANET study)

Hideki Iijima, Shinta Mizuno, Shinichiro Shinzaki, Katsuyoshi Matsuoka, Hiroki Tanaka, Fuminao Takeshima, Shingo Kato, Takehiro Torisu, Michio Nakagawa, Shiro Nakamura, Naoki Yoshimura, Taku Kobayashi, Akiko Shiotani, Fumihito Hirai, Sakiko Hiraoka, Minoru Matsuura, Yasuo Suzuki, Mamoru Watanabe, Tetsuo Takehara, Takayuk

Usefulness of serum leucine-rich alpha-2-glycoprotein (LRG) for monitoring the efficacy of adalimumab treatment in patients with Crohn's disease (PLANET study)

Shinichiro Shinzaki, Katsuyoshi Matsuoka, Hideki Iijima, Shinta Mizuno, Hiroki Tanaka, Fuminao Takeshima, Shingo Kato, Takehiro Torisu, Tomoo Nakagawa, Shiro Nakamura, Naoki Yoshimura, Taku Kobayashi, Akiko Shiotani, Fumihito Hirai, Sakiko Hiraoka, Minoru Matsuura, Yasuo Suzuki, Mamoru Watanabe, Tetsuo Takehara, Takayuki

Item 1 - 10 / 10
1